TXG vs. BLI, BRKR, BIO, BIO.B, OLK, LAB, CTKB, QTRX, EYPT, and PACB
Should you be buying 10x Genomics stock or one of its competitors? The main competitors of 10x Genomics include Berkeley Lights (BLI), Bruker (BRKR), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories (BIO.B), Olink Holding AB (publ) (OLK), Standard BioTools (LAB), Cytek Biosciences (CTKB), Quanterix (QTRX), EyePoint Pharmaceuticals (EYPT), and Pacific Biosciences of California (PACB). These companies are all part of the "analytical instruments" industry.
10x Genomics (NASDAQ:TXG) and Berkeley Lights (NASDAQ:BLI) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.
10x Genomics received 33 more outperform votes than Berkeley Lights when rated by MarketBeat users. Likewise, 52.56% of users gave 10x Genomics an outperform vote while only 26.67% of users gave Berkeley Lights an outperform vote.
10x Genomics has a net margin of -42.20% compared to Berkeley Lights' net margin of -124.74%. 10x Genomics' return on equity of -30.85% beat Berkeley Lights' return on equity.
10x Genomics currently has a consensus target price of $48.50, indicating a potential upside of 116.32%.
In the previous week, 10x Genomics had 8 more articles in the media than Berkeley Lights. MarketBeat recorded 8 mentions for 10x Genomics and 0 mentions for Berkeley Lights. 10x Genomics' average media sentiment score of 0.80 beat Berkeley Lights' score of 0.00 indicating that 10x Genomics is being referred to more favorably in the media.
84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 68.4% of Berkeley Lights shares are owned by institutional investors. 10.0% of 10x Genomics shares are owned by insiders. Comparatively, 17.6% of Berkeley Lights shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Berkeley Lights has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Berkeley Lights, indicating that it is currently the more affordable of the two stocks.
10x Genomics has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500. Comparatively, Berkeley Lights has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500.
Summary
10x Genomics beats Berkeley Lights on 11 of the 15 factors compared between the two stocks.
Get 10x Genomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
10x Genomics Competitors List
Related Companies and Tools